We are dedicated to developing innovative microbiome therapeutics that have the potential to transform lives.
To learn more about our work and find out if we are currently recruiting participants for a clinical trial you or a loved one may be interested in, please see below.
Recurrent C. diff
We are developing CP101, an investigational orally administered microbiome therapeutic for the prevention of recurrent C. difficile (C. diff) infection in adults. CP101 is designed to restore a diverse microbial community in the gut, which may help prevent recurrent C. diff.
PRISM4, a Phase 3 study of CP101 for the prevention of recurrent C. diff is currently enrolling participants who meet the study criteria.
If you or a loved one are interested in learning more about the PRISM4 study, you can:
Autism spectrum disorder
In September 2022, we announced the decision to suspend efforts to initiate a Phase 1 study in children with autism while we explore opportunities to leverage clinical data generated by ongoing third-party studies to inform our autism program strategy going forward. When additional information is available about our plans, we will share an update on our website.